Gilead Sciences, Inc GILD

NASDAQ US Health Care Biotechnology

$150.93 ▲ +0.83% (+$1.24)

Index member: S&P 500

Open $150.05

Prev Close $149.69

Day Range $148.02 – $151.00

52W Range $108.46 – $157.29

Market Cap $185.61B

P/E (TTM) 21.74

Beta 0.40

Div Yield 3.98%

EPS (TTM) $-2.66

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1992-01-22
Shares Out.	1,241,570,000
Website	gilead.com ↗
Phone	13026587581
Employees	17,000
Revenue	$7.80B
Gross Profit	$6.22B
Net Income	-$10.50B
Free Cash Flow	$12.94B
Total Assets	$49.36B
Total Liabilities	$37.62B
Equity	$11.74B

About Gilead Sciences, Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences, Inc is a publicly traded company under the ticker symbol GILD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.